Hub · Are peptides legal in Australia? Research peptide schedule status
What did the November 2025 PBAC decide on semaglutide?
The November 2025 Pharmaceutical Benefits Advisory Committee (PBAC) outcomes record a recommendation for semaglutide in a defined adult population with established cardiovascular disease and obesity. The entry identifies the brand as Wegovy and the sponsor as Novo Nordisk. This page records the November 2025 decision, read on 15 October 2026; that entry does not state an effective PBS listing date.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
01What is the scope of the…Contents
The November record concerns a defined application. The semaglutide entry runs across pages 36-38 in the November 2025 PBAC outcomes; its named brand is Wegovy and its sponsor is Novo Nordisk Pharmaceuticals (read 15 October 2026).
Key facts
| Decision record | PBAC meeting outcomes, November 2025, pages 36-38 |
|---|---|
| Recorded outcome | Recommended |
| Named substance and brand | Semaglutide; Wegovy (November 2025 PBAC outcomes) |
| Population in the recommendation | A defined adult population with established cardiovascular disease and obesity (November 2025 PBAC outcomes) |
| Publication page updated | 17 February 2026 (PBS publication page) |
| Source read | 15 October 2026 |
What is the scope of the November 2025 recommendation?
The November 2025 PBAC outcomes mark the semaglutide application as Recommended for adults with established cardiovascular disease and obesity, subject to the population restrictions recorded in the decision. The entry names Wegovy and Novo Nordisk Pharmaceuticals. The recommendation and its continuation occupy pages 36-38, checked on 15 October 2026.
This record sits within Peptides and Australian Law. The tirzepatide March 2026 decision is a separate committee record. The Schedule 4 explainer covers the separate scheduling document.
What dates does the published decision establish?
The PBS publication page identifies the meeting as November 2025 and gives 17 February 2026 as its update date. The semaglutide entry in the linked outcomes document states no effective PBS listing date. This is a dated decision summary, checked on 15 October 2026, with no claim about a later listing outcome.
The semaglutide SELECT design paper was published online on 17 July 2020, according to its PubMed publication record (Ryan et al., American Heart Journal, 2020). That is a trial publication date, separate from the committee record. The TRIUMPH-OUTCOMES status page records another trial's dated registry fields.
FAQ
Which semaglutide brand is named in this decision?
The November 2025 PBAC outcomes name Wegovy in the semaglutide entry on page 36 (read 15 October 2026).
Does this record establish a PBS listing date?
No effective PBS listing date is stated in the semaglutide entry in the November 2025 PBAC outcomes, pages 36-38 (read 15 October 2026).
Citations
1 sourcesRyan DH, Lingvay I, Colhoun HM, et al. American Heart Journal. 2020;229:61-69. SELECT trial: rationale and design; published online 17 July 2020.
doi:10.1016/j.ahj.2020.07.008
Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.